Meta Pixel

News and Announcements

Metrics Investors Look For In Assessing A Startup

  • Published December 12, 2022 6:45AM UTC
  • Publisher Osama Hassan
  • Categories Capital Raising Tips

What metrics and thresholds do VCs look for when assessing a startup for investment, e.g., “What should our monthly churn rate be for Series X?“ 🤔

This is a very common concern for those seeking capital that leads to a host of different questions being asked in the venture capital space❗

Andrew Yeo from AirTree has written a great piece in which he explains why VCs generally consider signals of product-market fit (PMF) over hard thresholds for individual metrics 🔥

These are the red flags and positive signals that Andrew highlights for venture investment across stages:

Red Flags 🛑 🚩

– Low or inconsistent MRR growth

– High and/or increasing churn rate

– High and/or increasing CAC payback periods 

– High CAC compared to LTV 

– Low or declining Gross Margin %

Rocket Ship Signals 🚀🧑‍🚀

– High rate of ARR growth, 2x-3x+ YoY

– Low churn or positive net dollar retention

– Fast CAC paybacks

– Improving LTV/CAC

– High or increasing Gross Margin %

For details, read the article: https://lnkd.in/ga7cVETX

Click here to view the original Linkedin post.

Looking for a platform to raise capital? Click here to discover how Wholesale Investor can help you.

Your capital engagement platform

With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now